Viveve Medical Launches GENEVEVE in Canada

Viveve Medical (NASDAQ:VIVE) will now offer the Canadian market of physicians and healthcare providers their GENEVEVE treatment.
As quoted in the press release:

Delivered by the internationally patented Viveve System, the GENEVEVE treatment improves sexual function by treating the vaginal introitus, after vaginal childbirth.
“We are excited to offer Canadian physicians and patients Viveve’s clinically proven cryogen cooled monopolar radiofrequency technology for the treatment of vaginal laxity, a common medical condition experienced by millions of women, that impacts their sexual satisfaction and quality of life,” said Patricia Scheller, chief executive officer of Viveve.

Click here to read the full press release.

Source: www.newswire.ca